N2-(2-氨基乙基)-N1,N1-二甲基乙二胺 | 24229-53-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N2-(2-氨基乙基)-N1,N1-二甲基乙二胺
• 英文名称: N2-(2-aminoethyl)-N1,N1-dimethyl-1,2-ethanediamine
• 英文别名: (2-aminoethyl)(N,N-dimethyl-2-aminoethyl)amine；N-(2-(dimethylamino)ethyl)ethylenediamine；N-(2-dimethylaminoethyl)ethylenediamine；1,1-dimethyl-1,4,7-triazaheptane；1,1-dimethyldiethylenetriamine；N,N-dimethyldiethylenetriamine；N'-[2-(dimethylamino)ethyl]ethane-1,2-diamine
• CAS: 24229-53-6
• 化学式: C₆H₁₇N₃
• 分子量: 131.221
• InChiKey: HLTMVWQXGLNLCU-UHFFFAOYSA-N

物化性质

• 沸点：
  115-120 °C(Press: 55 Torr)
• 密度：
  0.8990 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2921290000

反应信息

• 作为反应物：
  描述：

  N2-(2-氨基乙基)-N1,N1-二甲基乙二胺 在 palladium dihydroxide 吡啶 、 氢气 作用下， 以 溶剂黄146 为溶剂， 25.0~110.0 ℃ 、101.33 kPa 条件下， 反应 10.0h， 生成 2-(3-aminopropyl)-5-[[2-[[2-(dimethylamino)ethyl]amino]ethyl]amino]-7,10-dihydroxy anthra[1,9-cd]pyrazol-6(2H)-one
  参考文献：
  名称：

  蒽吡唑抗癌药。合成和构效关系对小鼠白血病。

  摘要：

  试图提供与米托蒽醌有关的蒽酮二酮的发色团修饰，以试图提供减少或没有心脏毒性的药剂，从而产生了新型的DNA结合物，蒽吡唑。它们的合成是通过从所需的1,4-或1,5-二氯-9,10-蒽二酮前体开始的两步缩合序列进行的。与单烷基肼反应得到氯蒽吡唑中间体，其随后与伯或仲烷基胺的缩合提供了目标“两臂”蒽吡唑。A环7,10-二羟基蒽唑是由胺与中间体5-氯-7,10-二羟基蒽唑的缩合反应衍生而来的，也可以是由中间体5-氯-7，10-双（苄氧基）蒽吡唑，然后氢解苄基保护基以提供目标化合物。在广泛的结构变异中，体外抗鼠L1210白血病（IC50 = 10（-7）-10（-8）M）以及体内P388白血病表现出强大的体外活性。通常，通过在N-2和C-5处的碱性侧链，侧链近端和远端氮之间的2至3个碳间隔基以及A环羟基化，可以最大限度地提高针对P388系的活性。除了具有针对P388品系的治疗活性外，更具活性的化合物

  DOI：

  10.1021/jm00384a021
• 作为产物：
  描述：

  二甲氨基氯乙烷盐酸 、 乙二胺 反应 2.0h， 以71.5%的产率得到N2-(2-氨基乙基)-N1,N1-二甲基乙二胺
  参考文献：
  名称：

  钳型YNP配合物催化乙醇脱氢偶联和酯加氢

  摘要：

  该“Y”给体基团（Y = -OMe，-set，-PPh 2，-NH 2，-NMe 2钳型钌，-py，吡咯烷基，喹啉基）络合物RuHCl（CO）[κ 3 -YNP对乙醇的脱氢均偶联和交叉偶联以及酯加氢反应中的催化活性具有显着影响。这些观察结果与催化反应的机理有关，并且本文为双官能催化剂以外球方式辅助酯C–O键形成/裂解提供了证据，这让人联想到蒂申科化学。

  DOI：

  10.1021/acscatal.6b02324

文献信息

• USE OF NITROGEN COMPOUNDS QUATERNISED WITH ALKYLENE OXIDE AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID AS ADDITIVES IN FUELS AND LUBRICANTS
  申请人：BASF SE

  公开号：US20160130514A1

  公开（公告）日：2016-05-12

  The invention relates to the use of quaternized nitrogen compounds as a fuel and lubricant additive or kerosene additive, such as in particular as a detergent additive, for decreasing or preventing deposits in the injection systems of direct-injection diesel engines, in particular in common rail injection systems, for decreasing the fuel consumption of direct-injection diesel engines, in particular of diesel engines having common rail injection systems, and for minimizing the power loss in direct-injection diesel engines, in particular in diesel engines having common rail injection systems; the invention further relates to the use as an additive for petrol, in particular for operation of DISI engines.

  该发明涉及将季铵化氮化合物用作燃料和润滑剂添加剂或煤油添加剂，特别是作为清洁剂添加剂，用于减少或预防直喷柴油发动机的喷射系统中的沉积物，在特定是在共轨喷射系统中，用于降低直喷柴油发动机的燃料消耗，特别是具有共轨喷射系统的柴油发动机，并用于减少直喷柴油发动机的功率损失，特别是在具有共轨喷射系统的柴油发动机中；该发明还涉及将其用作汽油添加剂，特别是用于DISI发动机的运行。
• [EN] LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE<br/>[FR] INHIBITEURS DE DÉMÉTHYLASE-1 SPÉCIFIQUE DE LA LYSINE ET LEUR UTILISATION
  申请人：ORYZON GENOMICS SA

  公开号：WO2011035941A1

  公开（公告）日：2011-03-31

  The invention relates to a compound of Formula (I): (A')x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A') is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, amido, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is -NH-; (L) is chosen from -CH2CH2-, -CH2CH2CH2-, and -CH2CH2CH2CH2-; and (D) is chosen from -N(-R1)-R2, -O-R3, and -S-R3, wherein: R1 and R2 are mutually linked to form a heterocyclic ring together with the nitrogen atom that R1 and R2 are attached to, wherein said heterocyclic ring has 0, 1, 2, or 3 substituents independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, cyano, alkoxy, haloalkyl, and haloalkoxy, or R1 and R2 are independently chosen from -H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein the sum of substituents on R1 and R2 together is 0, 1, 2, or 3, and the substituents are independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro; and R3 is chosen from -H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein R3 has 0, 1, 2, or 3 substituents independently chosen from -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)(C1-C6 alkyl), and fluoro; or an enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof. The compounds of the invention show inhibitory LSD1 activity, which makes them useful in the treatment or prevention of diseases such as cancer.

  该发明涉及一种化合物，其化学式为(I)：(A')x-(A)-(B)-(Z)-(L)-(D)，其中：(A)是杂环芳基或芳基；每个(A')（如果存在）独立地选择自芳基、芳基烷氧基、芳基烷基、杂环烷基、芳氧基、卤素、烷氧基、卤代烷基、环烷基、卤代烷氧基和氰基，其中每个(A')被0、1、2或3个取代基独立地选择自卤素、卤代烷基、芳基、芳基烷氧基、烷基、烷氧基、氰基、磺酰基、酰胺基和亚砜基；X为0、1、2或3；(B)为环丙基环，其中(A)和(Z)与(B)的不同碳原子形成共价键；(Z)为-NH-；(L)选择自-CH2CH2-、-CH2CH2CH2-和-CH2CH2CH2CH2-；(D)选择自-N(-R1)-R2、-O-R3和-S-R3，其中：R1和R2相互连接以与R1和R2附着的氮原子一起形成杂环环，所述杂环环有0、1、2或3个取代基，独立地选择自-NH2、NH(C1-C6烷基)、N(C1-C6烷基)(C1-C6烷基)、烷基、卤素、氰基、烷氧基、卤代烷基和卤代烷氧基，或R1和R2独立地选择自-H、烷基、环烷基、卤代烷基和杂环烷基，其中R1和R2的取代基总和为0、1、2或3，取代基独立地选择自-NH2、NH(C1-C6烷基)、N(C1-C6烷基)(C1-C6烷基)和氟；R3选择自-H、烷基、环烷基、卤代烷基和杂环烷基，其中R3有0、1、2或3个取代基，独立地选择自-NH2、NH(C1-C6烷基)、N(C1-C6烷基)(C1-C6烷基)和氟；或其对映体、非对映体或其混合物，或其药学上可接受的盐或溶剂。该发明的化合物显示出抑制LSD1活性，使其在治疗或预防癌症等疾病方面具有用途。
• [EN] COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT<br/>[FR] COMPOSITION POUR L'ÉLECTROGALVANISATION D'ALLIAGE D'ÉTAIN ET D'ARGENT COMPRENANT UN AGENT COMPLEXANT
  申请人：BASF SE

  公开号：WO2019185468A1

  公开（公告）日：2019-10-03

  An aqueous composition comprising (a) metal ions comprising tin ions and silver ions and (b) at least one complexing agent of formula (C1) R1-X1-S-X21[D1-X22-]nS-X3-R2, (C2) R1-X1-S-X31-D2-[X32-S-]nX3-R2, (C3) R3-X1-S-X41-[D3-X42-]nS-X3-R4 wherein X1, X3 are independently selected from a linear or branched C1-C12 alkanediyl, which may be unsubstituted or substituted by OH; X21, X22 are independently selected from X1, which may be further substituted by -X5-COOR12, -X5-SO2-O-R12, a C2 to C6 polyoxyalkylene group of formula -(O-CH2- CHR11)z-OH, or a combination thereof, and -X1-NH-CO-X6-CO-NH-X1-; X31, X32 are independently selected from a chemical bond and X1; X41, X42 are independently selected from X1; X5 is a linear or branched Ci to C10 alkyl; X6 is selected from X1 and a divalent 5 or 6 membered aromatic group; R1, R2 are independently selected from a monovalent 5 or 6 membered aromatic N- heterocyclic group comprising one N atom or two N atoms which are separated by at least one C atom, and its derivatives received by N-alkylation with a C1-C6- alkyl group, which may be substituted by --COOR12 or -SO2-O-R12, and which aromatic N- heterocyclic group may optionally further comprise, under the proviso that X21 is substituted by at least one OH, one S atom; R3, R4 are independently selected from a monovalent 5 or 6 membered aliphatic N- heterocyclic group comprising one N atom and one O atom; D1 is independently selected from S, O and NR10-; D2 is (a) a divalent 5 or 6 membered aliphatic heterocyclic ring system comprising 1 or 2 S atoms, or (b) a 5 or 6 membered aromatic heterocyclic ring system comprising at least two N atoms and optionally one or two S atoms; D3 is independently selected from S and NR10-; n is an integer of from 0 to 5; z is an integer from 1 to 50; R10 is selected from H and a linear or branched C1-C12 alkyl; R11 is selected from H and a linear or branched C1 to C6 alkyl; and R12 is selected from R10 and a cation.

  一种水性组合物，包括（a）包括锡离子和银离子的金属离子和（b）至少一种具有以下结构的络合剂：（C1）R1-X1-S-X21[D1-X22-]nS-X3-R2，（C2）R1-X1-S-X31-D2-[X32-S-]nX3-R2，（C3）R3-X1-S-X41-[D3-X42-]nS-X3-R4，其中X1、X3可独立地选择自线性或支链的C1-C12脂肪二亚基，可以未取代或被OH取代；X21、X22可独立地选择自X1，可以进一步被-X5-COOR12，-X5-SO2-O-R12，具有式-(O-CH2-CHR11)z-OH的C2到C6聚氧烷基，或其组合物取代，以及-X1-NH-CO-X6-CO-NH-X1-；X31、X32可独立地选择自化学键和X1；X41、X42可独立地选择自X1；X5是线性或支链的Ci到C10烷基；X6选择自X1和双价的5或6元芳香族基；R1、R2可独立地选择自包括一个N原子或两个N原子的单价5或6元芳香N-杂环基，通过N-烷基化与C1-C6烷基基团取代的衍生物，可以被--COOR12或-SO2-O-R12取代，该芳香N-杂环基可以选择性地进一步包括，在X21至少被一个OH取代的条件下，一个S原子；R3、R4可独立地选择自包括一个N原子和一个O原子的单价5或6元脂肪N-杂环基；D1可独立地选择自S、O和NR10-；D2是（a）包括1或2个S原子的双价5或6元脂肪杂环环系统，或（b）包括至少两个N原子和可选地一个或两个S原子的5或6元芳香杂环环系统；D3可独立地选择自S和NR10-；n是从0到5的整数；z是从1到50的整数；R10选择自H和线性或支链的C1-C12烷基；R11选择自H和线性或支链的C1到C6烷基；R12选择自R10和阳离子。
• MICRO/NANO MATERIALS, PRODUCTS OBTAINED BY COVALENTLY MODIFYING SURFACE OF MICRO/NANO MATERIALS WITH HYDROPHILIC MATERIALS, AND METHOD FOR MAKING SAME
  申请人：CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD.

  公开号：US20190077746A1

  公开（公告）日：2019-03-14

  Micro-nano materials, products obtained by covalently modifying the surfaces of micro/nano materials with hydrophilic materials, and methods for making the same. The micro/nano materials on the surfaces have carboxyl groups or/and pro-carboxyl groups which are converted into their active esters. The products are covalently modified by forming amide bonds between the active esters on the surfaces and the modification agents; where the modification agents are hydrophilic compounds and/or hydrophilic polymers bearing primary and/or secondary aliphatic amines. Monomers bearing carboxyl groups and/or pro-carboxyl groups are used to produce an adequate number of carboxyl groups and/or pro-carboxyl groups on the surface of a polymer material to be modified. The carboxyl groups and/or pro-carboxyl groups are converted into active esters. A reasonably-sized modification agent bearing primary and/or secondary amines, zwitterions and hydrophilic linear spacer arms is used to form amide bonds and obtain a covalently modified surface layer.

  微纳米材料，通过用亲水材料共价修饰微/纳米材料表面获得的产品，以及制备这些产品的方法。表面上的微/纳米材料具有羧基或/和前羧基，这些羧基或前羧基被转化为它们的活性酯。通过在表面上的活性酯和修饰剂之间形成酰胺键，共价修饰的产品；其中修饰剂是带有一次和/或二次脂肪胺基的亲水化合物和/或亲水性聚合物。使用带有羧基和/或前羧基的单体来产生足够数量的羧基和/或前羧基，以便在待修饰的聚合物材料表面上形成。将羧基和/或前羧基转化为活性酯。使用合理大小的带有一次和/或二次胺基、带有带电离子和亲水性线性间隔臂的修饰剂来形成酰胺键，并获得共价修饰的表面层。
• Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones
  申请人：Warner-Lambert Company

  公开号：US04556654A1

  公开（公告）日：1985-12-03

  Substituted anthra[1,9-cd]pyrazol-6(2H-ones have antimicrobial activity. Methods for their preparation, use and pharmaceutical compositions are disclosed.

  取代的蒽[1,9-cd]吡唑-6(2H)-酮具有抗微生物活性。公开了它们的制备方法、用途和药物组合物。